TGFβ engages MEK/ERK to differentially regulate benign and malignant pancreas cell function

Autor: Carolina Torres, Ronald D McKinney, Riley J. Mangan, Andrew M. Lowy, Ming-Sound Tsao, Daniel R. Principe, Barbara Jung, Brian DeCant, Hidayatullah G. Munshi, Paul J. Grippo, Andrew M. Diaz
Jazyk: angličtina
Rok vydání: 2017
Předmět:
0301 basic medicine
MAPK/ERK pathway
Male
Cancer Research
Epithelial-Mesenchymal Transition
MAP Kinase Signaling System
Blotting
Western
Fluorescent Antibody Technique
medicine.disease_cause
03 medical and health sciences
Mice
Growth factor receptor
Downregulation and upregulation
Transforming Growth Factor beta
Cell Line
Tumor
Genetics
medicine
Animals
Humans
Immunoprecipitation
Epithelial–mesenchymal transition
Extracellular Signal-Regulated MAP Kinases
Molecular Biology
Pancreas
biology
Transforming growth factor beta
Cell cycle
MAP Kinase Kinase Kinases
Immunohistochemistry
Mice
Mutant Strains
Mice
Inbred C57BL
Pancreatic Neoplasms
Disease Models
Animal
030104 developmental biology
Cell Transformation
Neoplastic
Cancer cell
biology.protein
Cancer research
Original Article
Female
Carcinogenesis
Carcinoma
Pancreatic Ductal
Zdroj: Oncogene
ISSN: 1476-5594
0950-9232
Popis: While TGFβ signals are anti-proliferative in benign and well-differentiated pancreatic cells, TGFβ appears to promote the progression of advanced cancers. To better understand dysregulation of the TGFβ pathway, we first generated mouse models of neoplastic disease with TGFβ receptor deficiencies. These models displayed reduced levels of pERK irrespective of KRAS mutation. Furthermore, exogenous TGFβ led to rapid and sustained TGFBR1-dependent ERK phosphorylation in benign pancreatic duct cells. Similar to results that our group has published in colon cancer cells, inhibition of ERK phosphorylation in duct cells mitigated TGFβ-induced upregulation of growth suppressive pSMAD2 and p21, prevented downregulation of the pro-growth signal CDK2 and ablated TGFβ-induced EMT. These observations suggest that ERK is a key factor in growth suppressive TGFβ signals, yet may also contribute to detrimental TGFβ signaling such as EMT. In neoplastic PanIN cells, pERK was not necessary for either TGFβ-induced pSMAD2 phosphorylation or CDK2 repression, but was required for upregulation of p21 and EMT indicating a partial divergence between TGFβ and MEK/ERK in early carcinogenesis. In cancer cells, pERK had no effect on TGFβ-induced upregulation of pSMAD2 and p21, suggesting the two pathways have completely diverged with respect to the cell cycle. Furthermore, inhibition of pERK both reduced levels of CDK2 and prevented EMT independent of exogenous TGFβ, consistent with most observations identifying pERK as a tumor promoter. Combined, these data suggest that during carcinogenesis pERK initially facilitates and later antagonizes TGFβ-mediated cell cycle arrest, yet remains critical for the pathological, EMT-inducing arm of TGFβ signaling.
Databáze: OpenAIRE
Externí odkaz: